Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 | MicrobiomeTrials← Back to trialsNCT02311621
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2014-11-25Est. Completion: 2023-11
Enrollment target: 65 participants Locations- Seattle Children's Hospital, Seattle, Washington, United States
Other microbiome trials you might be interested in
Neuroblastoma
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete respon…
Indianapolis, United StatesEst. completion Jun 2026
Refractory Solid TumorsRelapsed Solid TumorsRelapsed NeuroblastomaRefractory NeuroblastomaRelapsed RhabdomyosarcomaRefractory Rhabdomyosarcoma
The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agen…
Los Angeles, United StatesEst. completion Apr 2030
Neuroendocrine CarcinomasNeuroendocrine TumorsCarcinoma, NeuroendocrineCarcinoma, AdrenocorticalCarcinoma, Adrenal Cortical
Background:
Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal gl…
Bethesda, United StatesEst. completion Oct 30, 2027